Haemophilia A News and Research

RSS
Hemophilia A is an X-linked, recessive, bleeding disorder caused by a deficiency in the activity of coagulation factor VIII. Affected individuals develop a variable phenotype of hemorrhage into joints and muscles, easy bruising, and prolonged bleeding from wounds. The disorder is caused by heterogeneous mutations in the factor VIII gene which maps to Xq28.
Inhibitor Education Summits to address pertinent topics regarding hemophilia

Inhibitor Education Summits to address pertinent topics regarding hemophilia

Medgenics' EPODURE tissue Biopumps platform technology effective in maintaining hemoglobin levels

Medgenics' EPODURE tissue Biopumps platform technology effective in maintaining hemoglobin levels

Prevention and eradication of FVIII antibodies could improve hemophilia treatment

Prevention and eradication of FVIII antibodies could improve hemophilia treatment

FDA approves Helixate FS for routine prophylaxis in children with hemophilia A

FDA approves Helixate FS for routine prophylaxis in children with hemophilia A

Amsterdam Molecular Therapeutics reports 2009 half year financials

Amsterdam Molecular Therapeutics reports 2009 half year financials

NIH stimulus funding supports Emory - grants to advance research, create jobs, support students

NIH stimulus funding supports Emory - grants to advance research, create jobs, support students

Research supports world blood donor day message on blood safety

Research supports world blood donor day message on blood safety

Medgenics’ phase I/II clinical trial shows EPODURE continuous anemia treatment lasting 5 months in kidney disease patients

Medgenics’ phase I/II clinical trial shows EPODURE continuous anemia treatment lasting 5 months in kidney disease patients

New tissue engineering technique may help stem cells generate solid organs

New tissue engineering technique may help stem cells generate solid organs

Gene therapy for rheumatoid arthritis: promising results

Gene therapy for rheumatoid arthritis: promising results

CSL Behring receives FDA approval of RiaSTAP

CSL Behring receives FDA approval of RiaSTAP

A new method to control bleeding in hemophilia

A new method to control bleeding in hemophilia

FDA licenses Kogenate FS to prevent joint damage in children with hemophilia A

FDA licenses Kogenate FS to prevent joint damage in children with hemophilia A

Some Northern California colleges banning campus blood drives because of FDA's policy barring MSM

Some Northern California colleges banning campus blood drives because of FDA's policy barring MSM

Maxygen receives approval for trial of factor VIIa in UK

Maxygen receives approval for trial of factor VIIa in UK

CSL Behring study shows extended half-life recombinant VIIa leads to longer biologic activity

CSL Behring study shows extended half-life recombinant VIIa leads to longer biologic activity

Chemically modified protein may help people with hard-to-treat hemophilia

Chemically modified protein may help people with hard-to-treat hemophilia

An improved gene therapy agent from University of Florida

An improved gene therapy agent from University of Florida

Discovery of gene mutation which causes epilepsy and mental retardation - but only in women

Discovery of gene mutation which causes epilepsy and mental retardation - but only in women

FDA approves new formulation of genetically engineered version of Factor VIIa plasma protein

FDA approves new formulation of genetically engineered version of Factor VIIa plasma protein